BioSpace News Archive

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the second quarter 2021 after the market closes on Thursday, July 29, 2021

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2021 after market close on Thursday, August 5, 2021.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the second quarter ended June 30, 2021, and provided an overview of recent business highlights.

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 5, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021.

Lantern Pharma (NASDAQ: LTRN), announced today that it will host a conference call and live webcast on Thursday, July 29, 2021 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss financial and operating results for the second quarter ended June 30, 2021.

Ironwood Pharmaceuticals, Inc. announced it will host its second quarter 2021 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 5, 2021.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients.

Acorda Therapeutics, Inc. announced that it has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A to commercialize INBRIJA® 33 mg in Spain.

Innovative Health Sciences, LLC (“IHS” or the “Company”) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis™ Syringe Infusion System.

Today, Stryker makes a stop with its “SmartRobotics™ Stadium” booth at Chickasaw Bricktown Ballpark in Oklahoma City as part of its 10-city tour in partnership with Minor League Baseball™ (MiLB™